News
The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...
14h
Zacks.com on MSNHims & Hers Stock Surges 90.4% in 3 Months: What's Fueling the Rally?HIMS benefits from strong online revenue, subscriber growth, and global expansion moves to fuel its health platform momentum. However, challenges may hurt performance.
Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...
Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...
Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...
The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...
Explore more
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...
National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in. | Novo ...
Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results